1. |
Drug trials in paediatric patients: continuing issues |
|
Inpharma Weekly,
Volume &NA;,
Issue 1225,
2000,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1225,
2000,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
3. |
Interferon-α cost effective in children with chronic hepatitis C |
|
Inpharma Weekly,
Volume &NA;,
Issue 1225,
2000,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
4. |
ACE inhibitors good value for money in diabetic nephropathy |
|
Inpharma Weekly,
Volume &NA;,
Issue 1225,
2000,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1225,
2000,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
6. |
Linezolid - meeting the challenge of Gram-positive resistance |
|
Inpharma Weekly,
Volume &NA;,
Issue 1225,
2000,
Page 7-8
Pamela Hunter,
Preview
|
|
摘要:
Gram-positive pathogens with resistance to many of the current antibacterial agents continue to increase in prevalence and pose a threat in many hospitals. Resistance is frequently seen in strains ofStaphylococcus aureus, Streptococcus pneumoniaeand in enterococci. How to cope with such resistance was a major theme at the 5th International Congress on Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones [Seville, Spain; January 2000]. One of the new agents targeted at this problem is linezolid, an oxazolidinone which recently completed phase III studies in the US.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
7. |
Pleconaril promising in respiratory infections |
|
Inpharma Weekly,
Volume &NA;,
Issue 1225,
2000,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
8. |
Perioperative dipyrone reduces postoperative pain |
|
Inpharma Weekly,
Volume &NA;,
Issue 1225,
2000,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1225,
2000,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
10. |
Thalidomide - most significant drug in decades for multiple myeloma? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1225,
2000,
Page 11-12
Carmen Innes,
Preview
|
|
摘要:
Sparked by a study recently published in theNEJM,*the subject of thalidomide and its use in multiple myeloma has generated significant attention in the scientific community. Several presentations at the 41st Annual Meeting of the American Society of Hematology (ASH) [New Orleans, US; December 1999] confirmed or expanded on theNEJMstudy. Although the drug needs to undergo further clinical trials, researchers at the meeting were hailing thalidomide as the most significant drug in 2 decades for multiple myeloma therapy.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|